Skip to content
Off-topic for aiqbench

Off-topic for aiqbench

This story was gathered from a source we follow but falls outside AI and quantum coverage, so there is no aiqbench take for it.

AstraZeneca invests $2B in Summit to pair cancer ADCs with bispecific antibody

Dealroom.co1 min read

AstraZeneca invests $2B in Summit to pair cancer ADCs with bispecific antibody  Dealroom.co

Read the full article at Dealroom.co

Related coverage